MedXCell Science is a French Life science company active in the field of regenerative medicine. With the CHU of Montpellier as a shareholder and leveraging on its expertise, it is currently completing a clinical trial phase 2 (ADIPOA-2) for its allogeneic cell therapy treating mild to moderate knee osteoarthritis